Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 3805-3811, November 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLemore, T. L.
Right arrow Articles by Busbee, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLemore, T. L.
Right arrow Articles by Busbee, D. L.

Dissociation between Aryl Hydrocarbon Hydroxylase Activity in Cultured Pulmonary Macrophages and Blood Lymphocytes from Lung Cancer Patients1

Theodore L. McLemore2, R. Russell Martin3, Nelda P. Wray, Elroy T. Cantrell and David L. Busbee

Departments of Medicine [T. L. M., R. R. M., N. P. W.] and Microbiology and Immunology [R. R. M.], Baylor College of Medicine, Houston, Texas 77030, Veterans' Administration Hospital, Houston, Texas 77030 [T. L. M., N. P. W.], Department of Biological Sciences [D. L. B.], and the Genetics Center [D. L. B., E. T. C.], North Texas State University, Denton, Texas, and Department of Pharmacology, Texas College of Osteopathic Medicine, Fort Worth, Texas [E. T. C.]

The in vitro induction of aryl hydrocarbon hydroxylase was measured in pulmonary alveolar macrophages and peripheral blood lymphocytes from 14 cigarette smokers with primary lung cancer and 15 smokers with a variety of nonneoplastic pulmonary diseases. Enzyme levels were measured in cells cultured with or without the inducer benzanthracene. For both induced and noninduced cultures, there were no differences in mean levels of cultured macrophage or lymphocyte enzyme activity between noncancer and lung cancer patients. Absolute levels and fold induction of aryl hydrocarbon hydroxylase in cultured macrophages and lymphocytes from individual noncancer patients were positively correlated [noninduced (r = 0.640, p < 0.04), induced (r = 0.801, p < 0.001), and fold induction (r = 0.942, p < 0.001)]. However, comparison of these values in cultured macrophages and lymphocytes from individual lung cancer patients demonstrated no positive correlation [noninduced (r = 0.083, p > 0.3), induced (r = 0.306, p > 0.3), and fold induction (r = -0.625, p < 0.02)]. Comparison of enzyme activity in macrophages freshly lavaged from the lung and benzanthracene-induced activity in cultured macrophages revealed a positive correlation for both noncancer (r = 0.865, p < 0.005) and lung cancer (r = 0.971; p < 0.001) patients. Similarly, comparison of enzyme activity in fresh macrophages and fold induction values in cultured macrophages was also well correlated for both groups of patients (r = 0.876, p < 0.001 for non-cancer patients; r = 0.908, p < 0.001 for lung cancer patients). Multivariant analysis of enzyme characteristics in several tissues may be useful in lung cancer diagnosis and in assessment of lung cancer risk. However, the use of a single tissue such as lymphocytes for evaluation of the relationship between aryl hydrocarbon hydroxylase activity and cancer susceptibility is questionable.

1 Supported by NIH Grants CA-15784, HL-16938, and AI-12048, American Cancer Society Grant PDT-54, a grant from the Veterans' Administration Hospital, Houston, Texas, and a grant from the Council for Tobacco Research. Computational Assistance was provided by the CLINFO project and funded by NIH Division of Research Resources Contract NOL-RR-5-2118.

2 To whom requests for reprints should be addressed, at the Department of Biology/Environmental, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, 6727 Bertner, Texas Medical Center, Houston, Texas 77030. This research was done by Dr. McLemore in partial fulfillment of the requirements for the Ph.D. degree in Biochemistry at the Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston.

3 Supported by a NIH Research Career Development Award KO4-AI-70335.

Received 5/19/77. Accepted 7/28/78.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.